This prognostic study created optimized ensembles of calibrated random forest models to predict clinically significant prostate cancer (csPCa, grade group ≥2 PCa) using total prostate-specific antigen ...
Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high-risk real-world prostate cancer population. The silent burden: A SEER-based analysis of potential years ...
A non-DRE, voided urine, genomic assay to diagnose prostate cancer and to assess its aggressiveness.
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
Dear Dr. Roach: I am a 53-year-old healthy male, and I always request to check my PSA levels each year. My 57-year-old brother's new doctor denied his request for a routine PSA check on their initial ...
Prostate cancer: What are the symptoms and how is it treated as Jeremy Clarkson receives diagnosis? - Jeremy Clarkson has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results